Details

Autor(en) / Beteiligte

• Walter, Karolin
• Rodriguez-Aznar, Eva
• Ferreira, Monica S. Ventura
• Frappart, Pierre-Olivier
• Dittrich, Tabea
• Tiwary, Kanishka
• Meessen, Sabine
• Lerma, Laura
• Daiss, Nora
• Schulte, Lucas-Alexander
• Najafova, Zeynab
• Arnold, Frank
• Usachov, Valentyn
• Azoitei, Ninel
• Erkan, Mert
• Lechel, Andre
• Brümmendorf, Tim H.
• Seufferlein, Thomas
• Kleger, Alexander
• Tabarés, Enrique
• Günes, Cagatay
• Johnsen, Steven A.
• Beier, Fabian
• Sainz, Bruno
• Hermann, Patrick C.

Titel

Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells

Ist Teil von

• Cancers, 2021-06, Vol.13 (13), p.3145

Ort / Verlag

Basel: MDPI AG

Erscheinungsjahr

2021

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• To assess the role of telomerase activity and telomere length in pancreatic CSCs we used different CSC enrichment methods (CD133, ALDH, sphere formation) in primary patient-derived pancreatic cancer cells. We show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic knockdown or pharmacological inhibitor (BIBR1532), resulted in CSC marker depletion, abrogation of sphere formation in vitro and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (NANOG, OCT3/4, SOX2, KLF4) and telomerase, which is essential for the self-renewal of CSCs. Disruption of the balance between telomerase activity and stemness factors eliminates CSCs via induction of DNA damage and apoptosis in primary patient-derived pancreatic cancer samples, opening future perspectives to avoid CSC-driven tumor relapse. In the present study, we demonstrate that telomerase regulation is critical for the “stemness” maintenance in pancreatic CSCs and examine the effects of telomerase inhibition as a potential treatment option of pancreatic cancer. This may significantly promote our understanding of PDAC tumor biology and may result in improved treatment for pancreatic cancer patients.